This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

PDI, Inc. Launches EngageCE, New Division Fielding Clinical Educators To Improve Treatment Protocols

PARSIPPANY, N.J., March 3, 2011 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced the launch of a new division, EngageCE, that will offer expert clinical educators to work with health care providers in the management of chronic diseases in order to optimize patient care and outcomes. EngageCE clinical educators will help medical practices transition from providing routine health care to implementing recognized and recommended standards of care.

"We are proud to enhance our offerings with this latest service that expands the communications channels offered by PDI to reach health care practitioners," said Nancy Lurker, Chief Executive Officer of PDI, Inc. "As a company, we remain intensely focused on delivering value to our customers by developing, creating and acquiring the most effective tools and vehicles for communicating with physicians and other health care providers."

EngageCE will operate as a separate unit, the services of which align well with PDI's other promotional outsource services. These include: (i) on-the-ground dedicated and shared sales teams;(ii) Group DCA, a leader in e-detailing and digital communications; (iii) Pharmakon, offering interactive medical education programs among health care practitioners; and (iv) PDI VOICE, which offers teledetailing.

EngageCE will be led by John Beriont, with Robin Freeburg reporting into him.

Beriont joins PDI from Practice Therapeutics in Bridgewater, N.J., where he was President. During his tenure, he developed and led its clinical educator business and deployed the industry's largest clinical educator team. A seasoned industry professional, he has held positions in operations, sales and sales management at Johnson & Johnson and Bristol-Myers Squibb in a broad range of therapeutic areas. Beriont's experience also includes positions of increasing responsibility at Cegedim Dendrite, Health Products Research and Quintiles, where he developed significant competencies and experience in technology solutions, market analytics and field-based medical education solutions. He holds a B.A. from Gettysburg College and an M.B.A. from Rider University.

Freeburg comes to PDI from Practice Therapeutics, where she was Senior Vice President, Operations, and responsible for managing the clinical educator teams. A trained surgical/trauma Registered Nurse, Freeburg has also managed numerous other clinical educator projects with Quintiles. She holds a B.S. in Nursing from Elmhurst College, Elmhurst, Ill.

The primary focus of EngageCE will be to instill best-practice treatment standards and procedures among health care practitioners and engage in discussions on appropriate drug therapies. This will involve introducing new protocols that can proactively enhance patient and disease management, with the goals of preventing medical issues from becoming more serious and of improving patient outcomes. The secondary focus will be to provide patient education on medical treatments to improve patients' ownership of their disease.

Stock quotes in this article: PDII 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs